Clinical Trial Update: A Study to Assess the Pharmacokinetics of CC-122 in Subjects With Mild, Moderate, and Severe Renal Impairment [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study assessing CC-122 in subjects with mild, moderate, and severe renal impairment has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Renal Insufficiency

Drugs mentioned

• CC-122

Snippet

Sponsor: Celgene | Conditions: Renal Insufficiency | Phase 1 | Status: COMPLETED